Curaleaf Holdings Inc.

Curaleaf offers 0.3463 Curaleaf shares plus $0.75 in cash for each Aurora share, which, based on the 30-day volume-weighted average price on August 10, 2026, amounts to a valuation of $4.00 per Aurora share and a premium of 45%. The acceptance period runs until December 1, 2026; chairman and CEO Boris Jordan will hold a webcast for shareholders. Curaleaf says the combined company would operate in 17 countries and would have generated $1.5 billion in revenue and nearly $350 million in adjusted EBITDA for the twelve months ended June 30, 2026, with expected annual cost synergies of at least $40 million. Aurora reported declines in net revenue and adjusted EBITDA of 14% and 78%, respectively, in the four quarters to June 30, 2026. » Więcej na de.investing.com

Curaleaf has announced a 1-for-3 reverse stock split to be effective on or about June 5, 2026, intended to meet U.S. exchange minimum price requirements and enable a potential uplisting. The move will reduce outstanding common shares from 698,728,008 to approximately 232,909,336 and will proportionally adjust options and convertible instruments. The stock will continue trading under the ticker CURA on the Toronto Stock Exchange; the company reports a market capitalization of about $2.7 billion and trailing twelve‑month revenue of $1.29 billion. Analyst price targets cited in the report range from $3.86 to $4.77. » Więcej na de.investing.com

Curaleaf has appointed Torsten Greif, co-founder of Four 20 Pharma, to its board of directors. Four 20 Pharma, in which Curaleaf holds a majority stake, is a German cannabis producer with EU-GMP and GDP licences. Curaleaf intends to use Greif’s local expertise to advance the expansion of its European activities and the supply of EU-GMP‑certified medical cannabis to Germany and other markets. » Więcej na de.investing.com